Edward Arrowsmith

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh et al. · Annals of Oncology · 2016 · 143 citations · Full text

Advanced Esophageal, Surgical Oncology, Esophagus +9

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Scott S. Tykodi, Lucio Gordan, Robert Alter et al. · Journal for ImmunoTherapy of Cancer · 2022 · 126 citations · Full text

Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane et al. · Clinical Genitourinary Cancer · 2020 · 101 citations · Full text

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study

Toni K. Choueiri, David F. McDermott, Jaime R. Merchan et al. · The Lancet Oncology · 2023 · 96 citations

Urology, Genitourinary Cancer, Medicine +5

Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer

Andres Forero‐Torres, Jeffrey R. Infante, David Waterhouse et al. · Cancer Medicine · 2013 · 90 citations · Full text